Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18751145 | OPTIMIZED CYP4V2 GENE AND APPLICATION THEREOF | June 2024 | January 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18426287 | CHIMERIC ANTIGEN RECEPTOR T CELL AND CONSTRUCTION METHOD THEREOF, AND ANTITUMOR DRUG | January 2024 | November 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18410043 | RECOMBINANT ADENO-ASSOCIATED VIRAL VECTORS FOR TREATING BIETTI CRYSTALLINE DYSTROPHY | January 2024 | April 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18459685 | CARDIAC STEM CELLS FOR CARDIAC REPAIR | September 2023 | October 2024 | Allow | 14 | 2 | 2 | Yes | No |
| 18348929 | MICROBIOME MODULATION OF A HOST BY DELIVERY OF DNA PAYLOADS WITH MINIMIZED SPREAD | July 2023 | May 2024 | Allow | 10 | 0 | 1 | Yes | No |
| 18345366 | MINIGENE THERAPY | June 2023 | July 2025 | Allow | 24 | 1 | 1 | No | No |
| 18296579 | RNA-Guided Human Genome Engineering | April 2023 | April 2024 | Allow | 12 | 2 | 0 | Yes | No |
| 18115556 | NOVEL PRIME-BOOSTING REGIMENS INVOLVING IMMUNOGENIC POLYPEPTIDES ENCODED BY POLYNUCLEOTIDES | February 2023 | June 2025 | Abandon | 27 | 1 | 0 | No | No |
| 17932812 | METHODS AND COMPOSITIONS FOR KILLING A TARGET BACTERIUM | September 2022 | August 2024 | Abandon | 23 | 2 | 2 | No | No |
| 17858885 | METHODS AND COMPOSITIONS FOR KILLING A TARGET BACTERIUM | July 2022 | August 2024 | Abandon | 26 | 3 | 1 | No | No |
| 17858899 | METHODS AND COMPOSITIONS FOR KILLING A TARGET BACTERIUM | July 2022 | July 2024 | Abandon | 25 | 2 | 1 | Yes | Yes |
| 17808630 | ADENO-ASSOCIATED VIRUS PACKAGING SYSTEMS | June 2022 | April 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17749460 | CONSTRUCT AND SEQUENCE FOR ENHANCED GENE EXPRESSION | May 2022 | April 2025 | Allow | 35 | 2 | 1 | Yes | No |
| 17747646 | DNA VECTORS, TRANSPOSONS AND TRANSPOSASES FOR EUKARYOTIC GENOME MODIFICATION | May 2022 | June 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17735676 | METHODS FOR IN VITRO MEMORY B CELL DIFFERENTIATION AND TRANSDUCTION WITH VSV-G PSEUDOTYPED VIRAL VECTORS | May 2022 | February 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17722227 | USE OF THE AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 FOR REVACCINATION OF POPULATION (VARIANTS) | April 2022 | February 2023 | Abandon | 10 | 0 | 1 | No | No |
| 17716102 | METHODS FOR ENGINEERING HIGHLY ACTIVE T CELL FOR IMMUNOTHERAPHY | April 2022 | February 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17715218 | METHODS FOR ENGINEERING ALLOGENEIC AND HIGHLY ACTIVE T CELL FOR IMMUNOTHERAPHY | April 2022 | January 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17689837 | IMMUNE CELLS HAVING CO-EXPRESSED SHRNAS AND LOGIC GATE SYSTEMS | March 2022 | February 2023 | Abandon | 11 | 0 | 1 | No | No |
| 17575564 | Stem Cell Aggregates and Methods for Making and Using | January 2022 | September 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17565060 | MICROBIOME MODULATION OF A HOST BY DELIVERY OF DNA PAYLOADS WITH MINIMIZED SPREAD | December 2021 | May 2023 | Allow | 17 | 2 | 2 | Yes | No |
| 17555284 | DUAL EXPRESSION VECTOR FOR GENE AUGMENTATION FOR CRUMBS COMPLEX HOMOLOGUE 1 (CRB1) MUTATIONS | December 2021 | April 2023 | Abandon | 16 | 1 | 1 | No | No |
| 17457118 | Genetically Engineered Cells and Uses Thereof | December 2021 | November 2023 | Abandon | 24 | 2 | 1 | No | No |
| 17528588 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | November 2021 | February 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17506089 | METHODS AND COMPOSITIONS FOR CIRCULAR RNA MOLECULES | October 2021 | May 2023 | Allow | 19 | 2 | 1 | Yes | No |
| 17489607 | CHIMERIC ANTIGEN RECEPTOR-MODIFIED NK-92 CELLS TARGETING EGFR SUPER-FAMILY RECEPTORS | September 2021 | December 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17469648 | METHODS AND COMPOSITIONS FOR KILLING A TARGET BACTERIUM | September 2021 | February 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17468290 | ADENO-ASSOCIATED VIRUS VARIANTS AND METHODS OF USE THEREOF | September 2021 | August 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17382146 | NON-REPLICATING VIRUS-DERIVED PARTICLES AND USES THEREOF | July 2021 | July 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17364890 | Systems and Methods to Enhance RNA Stability and Translation and Uses Thereof | July 2021 | March 2025 | Abandon | 45 | 4 | 1 | No | Yes |
| 17331462 | HIGH THROUGHPUT ENGINEERING OF FUNCTIONAL AAV CAPSIDS | May 2021 | July 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17315030 | HUMAN ANTIBODY-PRODUCING CELL | May 2021 | February 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17239780 | NUCLEASE-MEDIATED REGULATION OF GENE EXPRESSION | April 2021 | January 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17233376 | NUCLEIC ACID CONSTRUCTS AND METHODS OF USE | April 2021 | February 2023 | Abandon | 22 | 2 | 0 | No | Yes |
| 17222727 | TARGETED TREATMENT OF LEBER CONGENITAL AMOUROSIS | April 2021 | July 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17220578 | NOVEL IMMUNOSTIMULATING VECTOR SYSTEM | April 2021 | July 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17219749 | COMPOSITIONS AND METHOD FOR MANIPULATING PIM-1 ACTIVITY IN CIRCULATORY SYSTEM CELLS | March 2021 | February 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17186332 | TREATMENT OF INTERVERTEBRAL DISC DEGENERATION | February 2021 | February 2025 | Abandon | 48 | 2 | 1 | Yes | No |
| 17272252 | COMPOSITION AND USE OF CAS PROTEIN INHIBITORS | February 2021 | June 2022 | Allow | 16 | 1 | 1 | Yes | No |
| 17175213 | TREATMENT OF AN IOP CONDITION | February 2021 | November 2024 | Abandon | 45 | 5 | 2 | No | No |
| 17173632 | METHOD FOR GENERATING T CELLS PROGENITORS | February 2021 | December 2022 | Allow | 22 | 3 | 1 | Yes | No |
| 17173668 | METHOD FOR GENERATING T CELL PROGENITORS | February 2021 | January 2023 | Allow | 23 | 4 | 1 | Yes | No |
| 17261659 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | January 2021 | October 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17138084 | BACTERIAL DELIVERY VEHICLES FOR IN VIVO DELIVERY OF A DNA PAYLOAD | December 2020 | June 2023 | Allow | 30 | 4 | 2 | Yes | No |
| 17133286 | CAR EXPRESSION VECTOR AND CAR-EXPRESSING T CELLS | December 2020 | February 2025 | Abandon | 50 | 4 | 0 | Yes | No |
| 17107696 | Modified Natural Killer Cells and Natural Killer Cell Lines Having Increased Cytotoxicity | November 2020 | September 2024 | Abandon | 46 | 2 | 1 | No | No |
| 17057973 | BLOCKADE OF CD2 SURFACE EXPRESSION AND EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY OF T-CELL MALIGNANCIES | November 2020 | June 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17056181 | CHIMERIC ANTIGEN RECEPTORS WITH MYD88 AND CD40 COSTIMULATORY DOMAINS | November 2020 | June 2025 | Allow | 55 | 3 | 1 | Yes | No |
| 17092712 | TREATMENT OF INTERVERTEBRAL DISC DEGENERATION | November 2020 | April 2024 | Abandon | 42 | 2 | 0 | No | No |
| 17092779 | TREATMENT OF INTERVERTEBRAL DISC DEGENERATION | November 2020 | May 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17087124 | Mesenchymal Stem Cells Expressing TNF-alpha Receptors | November 2020 | July 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 17031791 | Replicative Minicircle Vectors With Improved Expression | September 2020 | August 2023 | Allow | 35 | 2 | 0 | No | No |
| 17040341 | CHIMERIC ENGULFMENT RECEPTORS AND USES THEREOF FOR NEURODEGENERATIVE DISEASES | September 2020 | March 2024 | Abandon | 42 | 0 | 1 | No | No |
| 16981223 | EXPRESSION OF FOXP3 IN EDITED CD34+ CELLS | September 2020 | March 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 17005733 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | August 2020 | January 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 16988415 | Method of Redirecting T Cells to Treat HIV Infection | August 2020 | June 2024 | Allow | 46 | 2 | 1 | Yes | No |
| 16912321 | METHODS AND PRODUCTS FOR EXPRESSING PROTEINS IN CELLS | June 2020 | January 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 16899436 | METHODS AND COMPOSITIONS FOR KILLING A TARGET BACTERIUM | June 2020 | November 2022 | Abandon | 30 | 4 | 1 | Yes | No |
| 16897900 | Optimised Coding Sequence and Promoter | June 2020 | November 2024 | Allow | 53 | 2 | 1 | Yes | No |
| 16876079 | METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL FOR IMMUNOTHERAPY | May 2020 | October 2023 | Allow | 41 | 5 | 1 | Yes | Yes |
| 16869642 | MODIFIED MRNA FOR MULTICELL TRANSFORMATION | May 2020 | March 2023 | Abandon | 34 | 2 | 1 | No | No |
| 16759293 | CANCER-KILLING CELLS | April 2020 | August 2023 | Allow | 40 | 2 | 1 | Yes | No |
| 16852361 | STEM CELL CULTURE MEDIUM AND METHOD | April 2020 | September 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16825858 | NANOS KNOCK-OUT THAT ABLATES GERMLINE CELLS | March 2020 | May 2024 | Allow | 50 | 3 | 1 | Yes | No |
| 16801262 | Single-vector gene construct comprising insulin and glucokinase genes | February 2020 | July 2024 | Abandon | 53 | 4 | 2 | No | No |
| 16800840 | GENETICALLY MODIFIED MESENCHYMAL STEM CELLS EXPRESSING ALPHA-1 ANTITRYPSIN (AAT) | February 2020 | July 2023 | Abandon | 40 | 2 | 1 | No | No |
| 16788039 | PREPARATION OF LIBRARIES OF PROTEIN VARIANTS EXPRESSED IN EUKARYOTIC CELLS AND USE FOR SELECTING BINDING MOLECULES | February 2020 | June 2023 | Abandon | 40 | 0 | 1 | No | No |
| 16787647 | INHIBITORS OF DEK PROTEIN AND RELATED METHODS | February 2020 | December 2023 | Abandon | 46 | 3 | 0 | No | No |
| 16787960 | PREPARATION OF LIBRARIES OF PROTEIN VARIANTS EXPRESSED IN EUKARYOTIC CELLS AND USE FOR SELECTING BINDING MOLECULES | February 2020 | October 2023 | Allow | 44 | 2 | 1 | Yes | No |
| 16787806 | PREPARATION OF LIBRARIES OF PROTEIN VARIANTS EXPRESSED IN EUKARYOTIC CELLS AND USE FOR SELECTING BINDING MOLECULES | February 2020 | October 2023 | Allow | 45 | 2 | 1 | Yes | No |
| 16635886 | DNA VECTORS AND ELEMENTS FOR SUSTAINED GENE EXPRESSION IN EUKARYOTIC CELLS | January 2020 | February 2023 | Allow | 37 | 1 | 1 | Yes | No |
| 16718791 | STABLE CELL LINES FOR RETROVIRAL PRODUCTION | December 2019 | September 2023 | Abandon | 45 | 2 | 1 | No | No |
| 16705492 | PERSONALIZED ANTI-CANCER AGENT SCREENING SYSTEM | December 2019 | July 2023 | Abandon | 43 | 2 | 1 | No | No |
| 16698703 | Novel Synthetic Biology-Based ADCC Technology | November 2019 | January 2023 | Allow | 38 | 3 | 0 | Yes | No |
| 16696210 | METHODS OF TREATING DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE WITH PROTECTIVE PROTEIN/CATHEPSIN A (PPCA) | November 2019 | November 2022 | Abandon | 36 | 2 | 1 | No | Yes |
| 16679102 | AAV-BASED GENE THERAPY FOR MULTIPLE SCLEROSIS | November 2019 | June 2023 | Abandon | 43 | 1 | 1 | No | No |
| 16610819 | IMPROVED LENTIVIRUSES FOR TRANSDUCTION OF HEMATOPOIETIC STEM CELLS | November 2019 | January 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16605360 | NON-INVASIVE OPTOGENETIC STIMULATION METHOD TO REGULATE GLUCOSE METABOLISM IN THE LIVER AND BROWN ADIPOSE TISSUE | October 2019 | June 2024 | Allow | 56 | 3 | 1 | Yes | No |
| 16500238 | MINIGENE THERAPY | October 2019 | March 2023 | Allow | 42 | 1 | 1 | Yes | No |
| 16496141 | INTEGRATION OF MESA RECEPTORS AND PROMOTORS TO IMPLEMENT CUSTOMIZED CELLULAR FUNCTION | September 2019 | June 2025 | Allow | 60 | 7 | 0 | Yes | No |
| 16575624 | POLYPEPTIDES, CELLS, AND METHODS INVOLVING ENGINEERED CD16 | September 2019 | May 2024 | Allow | 56 | 4 | 0 | Yes | Yes |
| 16494203 | COMPOSITIONS AND METHODS FOR ENHANCED GENE EXPRESSION | September 2019 | May 2023 | Allow | 45 | 2 | 1 | Yes | No |
| 16485488 | METHOD FOR GENERATING T CELLS PROGENITORS | August 2019 | September 2024 | Abandon | 60 | 4 | 2 | No | No |
| 16482560 | Bioconjugation Methods for Targeted in Situ Therapeutic Delivery | July 2019 | June 2025 | Abandon | 60 | 5 | 2 | No | No |
| 16524645 | RECOMBINANT AAV VECTORS EXPRESSING OSTEOPROTECTIVE GENES, INCLUDING HAS2 AND LUBRICIN, USEFUL IN THE TREATMENT OF OSTEOARTHRITIS AND RELATED JOINT CONDITIONS IN MAMMALS | July 2019 | October 2023 | Allow | 50 | 5 | 1 | Yes | Yes |
| 16481617 | CARDIAC PROGENITOR CELLS HAVING ENHANCED p53 EXPRESSION AND USES THEREOF | July 2019 | May 2024 | Abandon | 57 | 3 | 1 | No | No |
| 16385864 | ENGINEERING OF HUMANIZED CAR T-CELL AND PLATELETS BY GENETIC COMPLEMENTATION | April 2019 | July 2023 | Abandon | 51 | 2 | 2 | No | No |
| 16331967 | POROUS MEMBRANE-BASED MACROMOLECULE DELIVERY SYSTEM | March 2019 | November 2022 | Abandon | 44 | 2 | 1 | No | No |
| 16324955 | Manipulated Immunoregulatory Element And Immunity Altered Thereby | February 2019 | February 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16251124 | CONDITIONED STEM CELL-DERIVED EXTRACT | January 2019 | January 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16248245 | TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WHICH HAS A DEOXYRIBONUCLEASE (DNase) ACTIVITY | January 2019 | October 2023 | Allow | 57 | 3 | 1 | Yes | No |
| 16317198 | METHOD FOR PRODUCING VACCINIA VIRUS EXPRESSING FOREIGN GENE | January 2019 | January 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16235453 | GENE EDITING AND TARGETED TRANSCRIPTIONAL MODULATION FOR ENGINEERING ERYTHROID CELLS | December 2018 | February 2023 | Abandon | 49 | 1 | 2 | No | No |
| 16312497 | GENETICALLY MODIFIED T LYMPHOCYTES | December 2018 | January 2023 | Allow | 48 | 4 | 0 | Yes | No |
| 16308326 | GENOME-EDITED NK CELL AND METHODS OF MAKING AND USING | December 2018 | February 2025 | Abandon | 60 | 5 | 1 | No | No |
| 16308373 | NON-INTEGRATING VIRAL DELIVERY SYSTEM AND METHODS RELATED THERETO | December 2018 | December 2023 | Allow | 60 | 2 | 1 | Yes | Yes |
| 16168549 | GENOMIC RNA PACKAGING ENHANCER ELEMENT | October 2018 | October 2023 | Allow | 60 | 3 | 1 | Yes | No |
| 16090941 | Adenoviral Vectors | October 2018 | August 2023 | Allow | 58 | 3 | 1 | Yes | Yes |
| 16090082 | LIPID NANOPARTICLE FORMULATIONS FOR CRISPR/CAS COMPONENTS | September 2018 | October 2022 | Abandon | 49 | 5 | 1 | Yes | No |
| 16089106 | CHIMERIC ANTIGEN RECEPTORS TARGETING CANCER | September 2018 | April 2024 | Abandon | 60 | 3 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NGUYEN, QUANG.
With a 62.5% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 19.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner NGUYEN, QUANG works in Art Unit 1631 and has examined 168 patent applications in our dataset. With an allowance rate of 58.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.
Examiner NGUYEN, QUANG's allowance rate of 58.9% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by NGUYEN, QUANG receive 3.01 office actions before reaching final disposition. This places the examiner in the 95% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by NGUYEN, QUANG is 45 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +72.9% benefit to allowance rate for applications examined by NGUYEN, QUANG. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.5% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 34.5% of cases where such amendments are filed. This entry rate is in the 44% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 25.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 26% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 74.2% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 60.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 50.0% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 10.1% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.